Custom cover image
Chemical biology : approaches to drug discovery and development to targeting disease / edited by Natanya Civjan
Resource type: Ressourcentyp: Buch (Online)Book (Online)Language: English Publisher: New York : John Wiley & Sons, 2012Edition: Online-AusgDescription: Online-Ressource (1 online resource (xiii, 509 p.)) : illISBN:- 9781283576055
- 1283576058
- 9781118437674
- 9781118101186
- 572
- SCI007000
- QP514.2
- QP514.2 .C58 2012
Contents:
Summary: NATANYA CIVJAN, PhD, is a freelance editor with a doctorate in biochemistry. Formerly with John Wiley & Sons, she developed and edited the Wiley Encyclopedia of Chemical Biology and was part of the team responsible for the Wiley Interdisciplinary Reviews, which won top prizes in publishing from the American Publishers Awards for Professional and Scholarly Excellence.Summary: Intro -- CHEMICAL BIOLOGY -- CONTENTS -- Preface -- Contributors -- PART I DRUG DISCOVERY AND DEVELOPMENT -- 1 The Role of Chemical Biology in Drug Discovery -- 1.1 INTRODUCTION -- 1.2 TARGET IDENTIFICATION AND VALIDATION -- 1.3 REAGENT AND ASSAY DEVELOPMENT -- 1.4 LEAD DISCOVERY -- 1.5 HIT TO LEAD/PROBE -- 1.6 LEAD OPTIMIZATION -- 1.7 CONCLUSIONS -- REFERENCES -- 2 Computational Approaches to Drug Discovery and Development -- 2.1 TARGET IDENTIFICATION -- 2.2 LEAD DISCOVERY -- 2.3 ADME/T OPTIMIZATION -- 2.4 THE FUTURE -- REFERENCES -- FURTHER READING -- SEE ALSO -- 3 Design and Selection of Small Molecule Inhibitors -- 3.1 VIRTUAL SCREENING IN SELECTING SMALL MOLECULE INHIBITORS -- 3.2 RECEPTOR-BASED VLS -- 3.3 LIGAND-BASED VIRTUAL SCREENING (2-D SIMILARITY SEARCH, 3-D PHARMACOPHORE SEARCH) -- 3.4 DESIGN OF SMALL MOLECULE INHIBITORS -- 3.5 SCAFFOLDS AND FRAGMENTS-BASED LEAD DESIGN -- 3.6 HYBRID DESIGN BASED ON KNOWN INHIBITORS -- 3.7 DE NOVO DESIGN -- 3.8 HIT AND LEAD OPTIMIZATION -- 3.9 STRUCTURE BASED -- 3.10 QSAR BASED -- 3.11 DESIGN OF SELECTIVE SMALL MOLECULE INHIBITORS -- 3.12 TARGETING THE DIFFERENCES IN THE BINDING POCKET -- 3.13 ENGINEERING SELECTIVITY USING CHEMICAL GENETICS -- 3.14 SUMMARY -- REFERENCES -- FURTHER READING -- 4 Lead Optimization in Drug Discovery -- 4.1 ADVANCES IN HIGH-THROUGHPUT SCREENING TECHNOLOGIES -- 4.2 SOLUTION-PHASE PARALLEL SYNTHESIS FOR LEAD OPTIMIZATION -- 4.3 EXPEDITED DRUG METABOLISM AND PHARMACOKINETICS -- 4.4 EXPEDITED, "CLOSED-LOOP" WORK FLOW FOR LEAD OPTIMIZATION -- REFERENCES -- FURTHER READING -- SEE ALSO -- 5 Pharmacokinetics of Drug Candidates -- 5.1 CLINICAL PHARMACOKINETICS -- 5.2 ROLE OF PK IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS -- 5.3 SUMMARY -- REFERENCES -- FURTHER READING -- 6 ADME Properties of Drugs -- 6.1 SOLUBILITY -- 6.2 PERMEABILITY -- 6.3 STABILITY.PPN: PPN: 809871599Package identifier: Produktsigel: ZDB-26-MYL | ZDB-30-PAD | ZDB-30-PQE | ZDB-38-EBR
CHEMICAL BIOLOGY; CONTENTS; Preface; Contributors; PART I DRUG DISCOVERY AND DEVELOPMENT; 1 The Role of Chemical Biology in Drug Discovery; 1.1 INTRODUCTION; 1.2 TARGET IDENTIFICATION AND VALIDATION; 1.3 REAGENT AND ASSAY DEVELOPMENT; 1.4 LEAD DISCOVERY; 1.5 HIT TO LEAD/PROBE; 1.6 LEAD OPTIMIZATION; 1.7 CONCLUSIONS; REFERENCES; 2 Computational Approaches to Drug Discovery and Development; 2.1 TARGET IDENTIFICATION; 2.2 LEAD DISCOVERY; 2.3 ADME/T OPTIMIZATION; 2.4 THE FUTURE; REFERENCES; FURTHER READING; SEE ALSO; 3 Design and Selection of Small Molecule Inhibitors
3.1 VIRTUAL SCREENING IN SELECTING SMALL MOLECULE INHIBITORS3.2 RECEPTOR-BASED VLS; 3.3 LIGAND-BASED VIRTUAL SCREENING (2-D SIMILARITY SEARCH, 3-D PHARMACOPHORE SEARCH); 3.4 DESIGN OF SMALL MOLECULE INHIBITORS; 3.5 SCAFFOLDS AND FRAGMENTS-BASED LEAD DESIGN; 3.6 HYBRID DESIGN BASED ON KNOWN INHIBITORS; 3.7 DE NOVO DESIGN; 3.8 HIT AND LEAD OPTIMIZATION; 3.9 STRUCTURE BASED; 3.10 QSAR BASED; 3.11 DESIGN OF SELECTIVE SMALL MOLECULE INHIBITORS; 3.12 TARGETING THE DIFFERENCES IN THE BINDING POCKET; 3.13 ENGINEERING SELECTIVITY USING CHEMICAL GENETICS; 3.14 SUMMARY; REFERENCES; FURTHER READING
4 Lead Optimization in Drug Discovery4.1 ADVANCES IN HIGH-THROUGHPUT SCREENING TECHNOLOGIES; 4.2 SOLUTION-PHASE PARALLEL SYNTHESIS FOR LEAD OPTIMIZATION; 4.3 EXPEDITED DRUG METABOLISM AND PHARMACOKINETICS; 4.4 EXPEDITED, "CLOSED-LOOP" WORK FLOW FOR LEAD OPTIMIZATION; REFERENCES; FURTHER READING; SEE ALSO; 5 Pharmacokinetics of Drug Candidates; 5.1 CLINICAL PHARMACOKINETICS; 5.2 ROLE OF PK IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS; 5.3 SUMMARY; REFERENCES; FURTHER READING; 6 ADME Properties of Drugs; 6.1 SOLUBILITY; 6.2 PERMEABILITY; 6.3 STABILITY; 6.4 CYTOCHROME P450 INHIBITION
6.5 OTHER ADME/TOX PROPERTIESREFERENCES; FURTHER READING; 7 Drug Transport in Living Systems; 7.1 MULTIDRUG TRANSPORTERS (MDTS); 7.2 INSIGHTS INTO STRUCTURES OF MDTS; 7.3 SUBSTRATE RECOGNITION: MULTIPLE DRUG BINDING PROTEINS; 7.4 TRANSPORT MECHANISMS OF MDTS; 7.5 PHYSIOLOGIC ROLES AND NATURAL SUBSTRATES; ACKNOWLEDGMENT; REFERENCES; FURTHER READING; 8 Blood-Brain Barrier: Considerations in Drug Development and Delivery; 8.1 CELLULAR PHYSIOLOGY OF THE BLOOD-BRAIN BARRIER; 8.2 DRUG DELIVERY TO THE BRAIN; 8.3 STRATEGIES TO IMPROVE CNS DRUG DELIVERY; ACKNOWLEDGMENTS; REFERENCES; FURTHER READING
SEE ALSO9 Pharmacokinetic Considerations: Methods and Systems of Controlled Drug Delivery; 9.1 GENERAL INTRODUCTION OF PHARMACOKINETICS/PHARMACODYNAMICS; 9.2 PHARMACOKINETIC/PHARMACEUTICAL DOSAGE FORM/PHARMACODYNAMIC CONSIDERATIONS IN THE DESIGN OF A CONTROLLED DRUG DELIVERY SYSTEM; 9.3 METHODS AND SYSTEMS OF CONTROLLED DRUG DELIVERY; 9.4 SUMMARY; REFERENCES; FURTHER READING; 10 Pharmaceuticals: Natural Products and Natural Product Models; 10.1 INTRODUCTION; 10.2 ANTIBACTERIAL AGENTS; 10.3 ANTIFUNGAL AGENTS; 10.4 ANTIMALARIALS; 10.5 ANTIVIRALS; 10.6 ANTIPAIN AGENTS; 10.7 ANTIOBESITY
10.8 ALZHEIMER'S AGENTS
No physical items for this record